The overwhelming majority of EGFR mutations found in lung cancer are acquired, meaning they arise spontaneously in lung cells during a person’s lifetime rather than being inherited from a parent. In rare cases, however, certain EGFR mutations can be passed down through families in a classic hereditary pattern, and these germline variants carry a measurable risk of lung cancer even in people who have never smoked. The distinction between acquired and inherited matters for treatment decisions, family screening, and understanding why some people develop lung cancer without obvious risk factors.
Most EGFR Mutations Are Somatic
When oncologists talk about EGFR mutations in lung cancer, they are almost always referring to somatic mutations. These changes happen in the DNA of individual lung cells over time and are not present in every cell of the body. They cannot be passed to children because they exist only in tumor tissue, not in eggs or sperm. The discovery that these somatic EGFR mutations drive a large share of non-small cell lung cancers reshaped how the disease is treated, turning molecular testing into a routine part of diagnosis.1PubMed Central. EGFR-mutated lung cancer: a paradigm of molecular oncology
The two most common somatic EGFR mutations are deletions in exon 19 and a point mutation called L858R in exon 21. Together, they account for the majority of EGFR-positive lung cancers and are sometimes called “sensitizing” mutations because tumors carrying them tend to respond well to targeted drugs. In one large analysis, sensitizing EGFR mutations were identified in thousands of patients with non-small cell lung cancer, while secondary resistance mutations like T790M appeared in a much smaller subset of those already on treatment.2PubMed. Prevalence and molecular correlates of acquired EGFR resistance mutations in non-small cell lung cancer (NSCLC) These resistance mutations are themselves acquired: they emerge under the selective pressure of therapy, not from inheritance.
The Rare Hereditary Form
A small number of families carry EGFR mutations in their germline, meaning the mutation is present in every cell of the body from birth and can be transmitted from parent to child. The best-studied hereditary EGFR mutation is T790M, the same mutation that commonly appears as an acquired resistance mechanism during treatment. When T790M is inherited rather than acquired, it acts differently. Instead of emerging as a response to drug therapy, it sits quietly in lung cells from birth and appears to raise the lifetime risk of developing lung cancer.
A landmark study first described a family with multiple cases of non-small cell lung cancer linked to germline transmission of EGFR T790M. In that family, four of six tumors analyzed carried a secondary somatic activating EGFR mutation that arose on the same copy of the gene as the inherited T790M, suggesting the germline mutation creates a favorable background for additional cancer-driving changes to accumulate.3PubMed Central. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR Other recognized germline EGFR mutations include V843I, R776H, and P848L, though T790M remains the most thoroughly characterized.4PubMed Central. Germline EGFR mutations in lung cancer
Penetrance and What It Means for Families
Carrying a germline EGFR mutation does not guarantee lung cancer. Researchers estimate the overall penetrance of germline EGFR T790M at roughly 23 percent, meaning that about one in four carriers develops cancer. Interestingly, penetrance appears higher in people who have never smoked (about 31 percent) than in those who have smoked (about 15 percent).5PubMed Central. Hereditary lung cancer syndrome targets never smokers with germline EGFR gene T790M mutations That pattern is counterintuitive at first glance: you might expect smoking to compound the genetic risk. The likely explanation is that smokers’ tumors tend to be driven by a different set of mutations altogether, so the EGFR germline mutation contributes a larger relative share of risk in people without tobacco exposure.
A larger study tracking 116 participants from 59 families confirmed that germline EGFR T790M follows a Mendelian inheritance pattern, meaning it passes from parent to child with a roughly fifty-fifty chance per offspring. Among confirmed or obligate carriers across 39 families, about 55 percent had developed lung cancer, with roughly half of those diagnosed by age 60.6PubMed Central. Germline EGFR Mutations and Familial Lung Cancer Those numbers look higher than the overall penetrance estimate because the study focused on confirmed carrier families already enriched for affected members. Regardless, the data make clear that hereditary EGFR mutations carry real clinical weight: families with clusters of lung cancer, especially in never-smokers, deserve genetic evaluation.
Who Gets Somatic EGFR Mutations and Why
Even when EGFR mutations are acquired rather than inherited, they do not strike at random across all populations. A large meta-analysis found that the prevalence of somatic EGFR mutations in non-small cell lung cancer was about 38 percent in Asian populations, compared with roughly 17 percent in Caucasians and a similar rate in African-Americans.7PubMed Central. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis Women are substantially more likely to harbor these mutations than men (about 44 percent versus 24 percent), and never-smokers far more likely than current or former smokers (about 49 percent versus 22 percent). Adenocarcinoma, the most common subtype of lung cancer, is the histology most strongly associated with EGFR mutations.
In never-smoking Asian women, EGFR mutations are the dominant driver of lung cancer, detected in roughly 63 percent of cases in one cohort study.8PubMed Central. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR The reasons behind these demographic skews are not fully understood. Some evidence points to inherited variations in genes involved in DNA repair and inflammation that may predispose certain populations to somatic EGFR mutations. One study in never-smoking Chinese populations identified a variant in the IL-6 gene that was specifically associated with EGFR-mutant lung adenocarcinoma, and familial lung cancers tend to have concurrent mutations in cancer-predisposition genes alongside EGFR changes.9PubMed. Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status10PubMed Central. Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review So while the EGFR mutation itself is somatic, a person’s inherited genetic background can tilt the odds of acquiring it.
Air Pollution and Environmental Triggers
A 2023 study in Nature proposed a mechanism that reframes how we think about acquired EGFR mutations and environmental exposure. The researchers found that fine particulate air pollution (PM2.5) does not necessarily cause EGFR mutations directly. Instead, PM2.5 appears to promote cancer in lung cells that already carry pre-existing EGFR mutations picked up through normal aging or other processes.11Nature. Particulate matter air pollution promotes EGFR-mutant lung cancer translation In mouse experiments, PM2.5 exposure triggered immune cells in the lung to release inflammatory signals that essentially “woke up” these dormant mutant cells, pushing them toward tumor formation.12PubMed Central. Air pollution, EGFR mutation, and cancer initiation
This finding has significant implications. It suggests that many people may walk around with EGFR-mutated cells in their lungs without ever developing cancer, and that environmental insults like air pollution act as a trigger pushing those pre-existing mutations toward malignancy. It also helps explain why EGFR-mutant lung cancer is common in never-smokers: the mutations may not require tobacco carcinogens to form, and a different environmental exposure entirely could be the match that lights the fire.
Radon, another environmental carcinogen commonly associated with lung cancer, has a less clear relationship with EGFR mutations. Studies of never-smoking and former-smoking women found that neither radon nor passive-smoking exposure was consistently associated with EGFR mutations in lung tumors.13PubMed Central. EGFR Somatic Mutations in Lung Tumors: Radon Exposure and Passive-smoking in Former- and Never-smoking U.S. Women A European study found suggestively higher radon levels in patients with one particular EGFR mutation subtype (exon 19 deletions) compared with another, but the difference did not reach conventional levels of statistical significance.14European Respiratory Journal. Residential radon, EGFR mutations and ALK alterations in never-smoking lung cancer cases Unlike PM2.5, radon does not yet have a convincing mechanistic link to EGFR-driven cancer specifically.
Developmental Mosaicism as a Third Category
Beyond the clean hereditary-versus-acquired distinction, researchers have identified a third possibility that blurs the boundary. A 2024 study in Nature Cancer examined patients who developed multiple separate EGFR-mutant primary lung tumors, which is unusual because most acquired mutations give rise to a single tumor. Using sophisticated lineage-tracing techniques, the researchers found that in four patients, the EGFR mutation likely arose very early in embryonic development, before the lung was fully formed. This created a mosaic: patches of lung tissue carrying the EGFR mutation scattered across the organ, each capable of independently progressing to cancer.15PubMed Central. Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors
These mosaic mutations are technically not germline because they are not present in every cell and cannot be passed to offspring. But they are not typical somatic mutations either, since they appear to have arisen during embryonic development rather than in adult life. The researchers proposed that a fully activating EGFR mutation may arise early during lung development, creating a population of mutant cells distributed throughout the adult organ.16PubMed Central. Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors For patients who present with multiple EGFR-mutant tumors, this mechanism raises important clinical questions about whether they need different surveillance or treatment strategies compared to someone with a single tumor.
How Treatment Depends on Mutation Origin
For patients with acquired sensitizing EGFR mutations, targeted drugs called tyrosine kinase inhibitors have transformed outcomes. Osimertinib, a third-generation inhibitor, has become a standard first-line treatment. In a pivotal trial, patients receiving osimertinib had a median overall survival of about 39 months, compared with roughly 32 months for those on older-generation drugs.17PubMed. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC Real-world data from Japan show similar overall survival between first-line osimertinib and sequential use of older drugs followed by osimertinib later, suggesting flexibility in treatment sequencing.18PubMed Central. Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01
For patients with germline EGFR T790M, the treatment picture is more complicated. T790M is the very mutation that makes tumors resistant to first-generation tyrosine kinase inhibitors. Osimertinib was specifically designed to overcome acquired T790M resistance, so it is a logical option for patients whose tumors carry T790M from the germline. But a germline mutation cannot be “eliminated” the way a somatic one can, because it exists in every cell. Patients with hereditary EGFR mutations may face lifelong cancer risk in both lungs, not just a single tumor event, and this changes conversations about screening, prevention, and long-term management.
Resistance eventually develops regardless of mutation origin. When tumors progress on osimertinib, the resistance mechanisms are diverse. In one study, about a third of patients retained T790M at progression, and among those, roughly 70 percent had acquired yet another new mutation, EGFR C797S.19JAMA Oncology. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib Others lost T790M entirely and developed resistance through completely different pathways, including transformation into small cell lung cancer or activation of alternative growth signals.20PubMed Central. Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies The sheer variety of escape routes tumors find underscores why ongoing molecular monitoring matters.
Tumor Heterogeneity and Why It Complicates Things
Even within a single tumor, not all cancer cells carry the same EGFR mutation. This intratumoral heterogeneity means that a biopsy might detect an EGFR mutation in one region of the tumor while cells in another region carry a different mutation or no EGFR mutation at all. Research has shown that patients whose tumors have this kind of mixed EGFR-mutation pattern have significantly shorter responses to targeted therapy and shorter survival compared with patients whose tumors are more genetically uniform.21PubMed Central. Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Heterogeneity also feeds into resistance. As a targeted drug kills cells carrying the sensitizing mutation, cells with different genetic features survive and expand. Comprehensive genomic profiling has revealed that many tumors carry concurrent genetic alterations beyond the primary EGFR mutation, and these can drive primary resistance from the very start of treatment.22PubMed Central. Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC This is why liquid biopsies, which sample tumor DNA circulating in the blood, are increasingly used to capture a broader snapshot of the tumor’s genetic diversity than a single tissue biopsy can provide.
When Liquid Biopsy Finds Something Unexpected
Liquid biopsy was designed to profile tumor mutations from a blood draw, but it sometimes picks up germline mutations as well. Because the test sequences circulating DNA, it cannot always tell whether a mutation originated in the tumor or was inherited. Distinguishing the two typically depends on the fraction of DNA carrying the mutation: germline mutations tend to appear at roughly 50 percent of reads (since they exist on one of two gene copies in every cell), while somatic mutations usually appear at lower, more variable fractions. But this rule is not foolproof, and several groups have developed specialized algorithms to improve the sorting.23Clinical Cancer Research. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
When a liquid biopsy incidentally uncovers what looks like a germline mutation, it raises questions that go well beyond the cancer being treated. A hereditary cancer-predisposition finding has implications for the patient’s blood relatives, who may want to know whether they carry the same mutation and what their own cancer risk looks like. Managing this kind of incidental information requires genetic counseling, confirmatory testing with a dedicated germline test, and sensitive communication with families.24PubMed Central. Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications Oncology teams are still working out the best protocols for handling these situations, since liquid biopsy was never designed as a genetic screening tool for inherited risk.
EGFR Mutations Beyond Lung Cancer
While the discussion of EGFR mutations centers heavily on lung cancer, the gene plays a role in other malignancies as well. In glioblastoma, the most aggressive form of brain cancer, amplification of EGFR and a specific mutant form called EGFRvIII occur frequently.25PubMed Central. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies These are somatic alterations as well, but they differ from the lung cancer mutations in their mechanism: rather than a subtle point mutation that makes the receptor overactive, glioblastoma cells often carry extra copies of the entire gene or a truncated version that is permanently switched on. The targeted drugs that work in EGFR-mutant lung cancer have not proven effective in glioblastoma, partly because the underlying biology is so different.
EGFR overactivity also contributes to some head and neck cancers, colorectal cancers, and pancreatic cancers, though the specific mutations and mechanisms differ from case to case. In all these contexts, the mutations are acquired. The hereditary EGFR story is, as far as current evidence shows, essentially a lung cancer phenomenon, centered on germline T790M and a handful of related variants. Whether future research will uncover germline EGFR mutations that predispose to cancers outside the lung remains an open question.